Valuation: Harbin Gloria Pharmaceuticals Co., Ltd

Market Cap 6.58B 988M 885M 817M 741M 1.38B 94.11B 1.4B 9.77B 3.89B 49.27B 3.71B 3.63B 156B P/E 2024
24.2x
P/E 2025 18.2x
Enterprise Value 5.74B 863M 772M 713M 646M 1.2B 82.12B 1.22B 8.53B 3.4B 42.99B 3.24B 3.17B 136B EV / Sales 2024
2.12x
EV / Sales 2025 2.82x
Free-Float
90.2%
Yield 2024 *
-
Yield 2025 -
08-26 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2026 CI
04-27 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
04-14 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Full Year Ended December 31, 2025 CI
01-15 Harbin Gloria Pharmaceuticals Co., Ltd Approves Election of Xu Yuhong as Independent Director, Effective 14 January 2026 CI
28/10/25 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Nine Months Ended September 30, 2025 CI
26/08/25 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the Half Year Ended June 30, 2025 CI
04/06/25 Harbin Gloria Pharmaceuticals Gets Right to Market Eisai's Mecobalamin Injection MT
27/05/25 Harbin Gloria Pharmaceuticals Signs Co-Promotion Deal for Lipid Drug MT
25/04/25 HARBIN GLORIA PHARMACEUTICALS Co., LTD Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
17/03/25 HARBIN GLORIA PHARMACEUTICALS Co., LTD Elects Liu Yueyin as A Non-Independent Director CI
14/03/25 Tranche Update on HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback Plan announced on October 22, 2024. CI
12/03/25 HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback announced on October 22, 2024, has closed with 32,307,224 shares, representing 1.42% for CNY 79.99 million. CI
10/03/25 Tranche Update on HARBIN GLORIA PHARMACEUTICALS Co., LTD's Equity Buyback Plan announced on October 22, 2024. CI
1 day+1.37%
1 week-6.94%
Current month-19.18%
1 month-15.71%
3 months+1.72%
6 months-21.75%
Current year-3.91%
1 week 2.87
Extreme 2.87
3.24
1 month 2.87
Extreme 2.87
3.78
Current year 2.37
Extreme 2.37
5.1
1 year 2.37
Extreme 2.37
5.1
3 years 1.66
Extreme 1.66
5.1
5 years 1.66
Extreme 1.66
5.1
10 years 1.66
Extreme 1.66
9.8
Manager TitleAgeSince
Chief Executive Officer 53 25/12/2022
Corporate Officer/Principal 42 17/04/2018
Corporate Officer/Principal 40 22/05/2019
Director TitleAgeSince
Director/Board Member 40 13/03/2025
Director/Board Member 53 10/11/2022
Director/Board Member 42 10/11/2022
Date Insider Type Main position Quantity % Market Cap. Importance
02/07/25 Sell 587,500 0.0283%
02/07/25 Sell

Director

259,600 0.0125%
02/07/25 Sell 587,500 0.0283%
Change 5-day change 1-year change 3-year change Capi.($)
+1.37%-6.94%-7.23%+21.40% 973M
+0.50%+0.36%+55.89%+129.96% 1,143B
+0.86%+4.50%+42.43%+86.15% 647B
-0.14%-1.07%+25.42%+105.85% 506B
-0.05%+2.28%+49.14%+67.74% 384B
-0.63%-4.97%+60.15%+37.06% 350B
+0.34%+2.15%+25.26%+54.27% 293B
-0.45%+1.16%+1.74%+26.08% 265B
+0.87%+2.94%+55.18%+72.74% 242B
+0.08%+1.72%+32.15%+107.78% 197B
Average +0.43%+0.46%+34.01%+70.90% 402.85B
Weighted average by Cap. +0.46%+0.71%+42.62%+89.00%

Financials

2024 2025
Net sales 2.44B 367M 328M 303M 275M 512M 34.92B 520M 3.63B 1.44B 18.28B 1.38B 1.35B 57.86B 2.14B 321M 287M 265M 240M 448M 30.55B 455M 3.17B 1.26B 15.99B 1.2B 1.18B 50.63B
Net income 233M 34.98M 31.3M 28.89M 26.2M 48.84M 3.33B 49.63M 346M 138M 1.74B 131M 128M 5.52B 377M 56.64M 50.69M 46.79M 42.43M 79.08M 5.39B 80.37M 560M 223M 2.82B 212M 208M 8.94B
Net Debt -509M -76.44M -68.41M -63.14M -57.26M -107M -7.28B -108M -756M -301M -3.81B -287M -281M -12.06B -838M -126M -113M -104M -94.34M -176M -11.99B -179M -1.24B -496M -6.28B -472M -463M -19.87B
Projected Income Statement - Annual - Harbin Gloria Pharmaceuticals Co., Ltd
Logo Harbin Gloria Pharmaceuticals Co., Ltd
HARBIN GLORIA PHARMACEUTICALS Co Ltd is a China-based company principally engaged in the research, development, production and sale of pharmaceuticals. The Company operates its businesses through three segments. The Traditional Chinese Medicine segment's main product is Annao Pills and Tablets. The Chemical Pharmaceuticals segment's products include cardiovascular and cerebrovascular drugs, musculoskeletal drugs, vitamins, electrolytes, analgesics, anti-infectives, anti-tumor drugs and others. The Others segment engages in pharmaceutical research and development, clinical services and others. The Company distributes its products within the domestic market and to overseas markets.
Employees
2,350
Date Price Change Volume
28/10/26 CN¥2.950 +1.37% 142,305,400
27/10/26 CN¥2.910 -3.32% 118,166,342
26/10/26 CN¥3.010 -2.27% 136,398,152
23/10/26 CN¥3.080 +1.32% 203,469,986
22/10/26 CN¥3.040 -6.17% 242,267,717

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Harbin Gloria Pharmaceuticals Co., Ltd
  1. Stock Market
  2. Stocks
  3. 002437 Stock